Early reduction of neurohumoral factors plays a key role in mediating the efficacy of β-blocker therapy for congestive heart failure

American Heart Journal

Volumn 131, Issue 2, 1996, Pages 329-336

  Yoshikawa, Tsutomu ^a   Handa, Shunnosuke ^b   Anzai, Toshihisa ^b   Nishimura, Hiroshi ^b   Baba, Akiyasu ^b   Akaishi, Makoto ^b   Mitamura, Hideo ^b   Ogawa, Satoshi ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARTEOLOL; ENALAPRIL; NEUROHORMONE; NIPRADILOL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILE FORCE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY;

EID: 0030049090     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90362-2     Document Type: Article

References (30)

1. Cohn JN, Levine B, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984;311:819-23.
2. The CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
3. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-10.
4. V-HeFT VA Cooperative Study Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Circulation 1993;87(suppl VI):VI-40-8.
5. Waagstein F, Hjarmarson A, Varnauskas E, Wallentin I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
6. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483-90.
7. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjarmarson A. Long-term β-blockade in dilated cardiomyopathy. Circulation 1989; 80:551-63.
8. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
9. CIBIS Investigators. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994; 90:1765-73.
10. Earley KJ, Gunasegarum S, Tennar TE. Determination of beta adrenoceptor density on rabbit mononuclear leukocytes. J Pharmacol Methods 1988;19:193-203.
11. Scatchard G. The attractions of proteins for molecules and ions. Ann NY Acad Sci 1949;51:660-72.
12. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
13. Eichhorn EJ, McGhie A, Bedotto JB, Corbett JR, Malley CR, Hatfield BA, Deitchman D, Willard JE, Grayburn PA. Effects of bucindolol on neurohumoral activation in congestive heart failure. Am J Cardiol 1991;67:67-73.
14. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
15. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamic and myocardial metabolism during long-term betaadrenergic blockade in severe heart failure. J Am Coll Cardiol 1991; 18:1059-66.
16. Man i' nt veld AJ, van den Meiracker A, Schalekamp M. The effects of β blockers on total peripheral resistance. J Cardiovasc Pharmacol 1986;8(suppl 4):S49-60.
17. Uchida Y, Nakamura M, Shimizu S, Shirasawa Y, Fujii M. Vasoactive and β-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-benzopyram (K-351), new antihypertensive agent. Arch Int Pharmacodyn 1983;262:132-49.
18. Yabuuchi Y and Kinoshita D. Cardiovascular studies of 5-(3-tert-buty-lamino-2-hydroxy) propoxy-3, 4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent β-adrenergic blocking agent. Jpn J Pharmacol 1974;24:853-61.
19. 2-adrenoceptors. Endocrinology 1992;130:2426-8.
20. Kishimoto I, Yoshimasa T, Suga S, Itoh H, Nakao K. Down-regulation of natriuretic peptide receptor and augmentation of biological response of natriuretic peptide via β2-adrenergic receptor in vascular smooth muscle cells [Abstract]. Circulation 1993;88(suppl I):I-182.
21. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993;71:23C-9C.
22. Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. β-Blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation 1991;83:2021-8.
23. 1-selectivity is not essential to achieve therapeutic efficacy with betablockade therapy for idiopathic dilated cardiomyopathy. Cardiology 1995;86:217-23.
24. Imperato-McGinley J, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED Jr. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med 1987; 316:793-7.
25. SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88:2277-83.
26. Mann DL, Kent RL, Parsons B, Cooper GIV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
27. 2+ overload. Circ Res 1994;75:324-34.
28. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
29. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure: reversal of sympathetic-induced alterations of immunologic function. Circulation 1994;90:1774-80.
30. 125iodocyanopindolol. Life Sci 1981;29:2189-98.